Women’s health has been stuck in the shadows for decades, boxed into maternity, carved up into specialties, and patched with “wellness” apps that don’t touch the real pain points. Visana Health looked at that status quo and decided to torch it. Not with hype, but with a nationwide medical group built to treat the conditions employers dread and women actually live with: menopause, PCOS, endometriosis. High-cost, complex, overlooked. Visana Health is showing those costs can be cut without cutting quality, and the numbers are too sharp to ignore.
Founded in 2019 by Joe Connolly and Shelly Lanning, the Minneapolis-based company just closed a $24M Series A led by Noro-Moseley Partners, with The Cigna Group Ventures and Intermountain Ventures joining, plus returning backers Flare Capital Partners and Frist Cressey Ventures. Total raise: $34.1M since its $10.1M seed in 2023. Connolly’s drive came from his mother’s 25-year fight with endometriosis; Lanning brings 20+ years of healthcare ops and venture chops. Together, they built a clinic model employers and insurers can’t ignore.
The reach speaks for itself. National/regional health plans covering 35M+ lives. Adoption by 40+ employers covering 1M+ members. Projected to serve ~50K women in 2025. The outcomes hit harder: employer medical costs down 34%, unnecessary procedures slashed 78%, annual savings per enrollee >$2,400. That’s a 4:1 ROI for payers and employers. And patients? A Net Promoter Score of 91, women finally getting care they trust.
Visana Health’s leadership team makes it clear this isn’t a lucky break. With Dr. Barbara Levy as Chief Medical Officer and Dr. Chevon Rariy as Chief Clinical Innovation Officer, the team is scaling beyond women’s health basics. Series A funds will drive expansion into weight management, cardiometabolic care, diabetes, thyroid, and cardiovascular conditions. AI will keep sharpening documentation, streamlining workflows, and giving clinicians back time that usually dies in EMRs.
The signal is undeniable. Women’s health is no longer niche, no longer a “cost center.” It’s a multi-billion dollar market, waiting for operators who can prove outcomes and economics align. Visana Health isn’t pitching theory, they’re delivering evidence. This isn’t just a funding headline, it’s a marker of where healthcare is heading: better outcomes at lower cost, with women finally at the center.
